Cited by 1,509Acute Myocardial Infarction ResearchCardiac Health and Mental HealthCardiac Ischemia and Reperfusion

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

beta Blockade after myocardial infarction: systematic review and meta regression analysis

Open access

Freemantle, N., Cleland, J., Young, P., Mason, J., Harrison, J.·1999·BMJ

DOI 10.1136/bmj.318.7200.1730PMC PMC31101

Open this paper in CoChat — free account Open PDF

Abstract

OBJECTIVES: To assess the effectiveness of beta blockers in short term treatment for acute myocardial infarction and in longer term secondary prevention; to examine predictive factors that may influence outcome and therefore choice of drug; and to examine the clinical importance of the results in the light of current treatment. DESIGN: Systematic review of randomised controlled trials. SETTING: Randomised controlled trials. SUBJECTS: Patients with acute or past myocardial infarction. INTERVENTION: beta Blockers compared with control. MAIN OUTCOME MEASURES: All cause mortality and non-fatal reinfarction. RESULTS: Overall, 5477 of 54 234 patients (10.1%) randomised to beta blockers or control died. We identified a 23% reduction in the odds of death in long term trials (95% confidence interval 15% to 31%), but only a 4% reduction in the odds of death in short term trials (-8% to 15%). Meta regression in long term trials did not identify a significant reduction in effectiveness in drugs with cardioselectivity but did identify a near significant trend towards decreased benefit in drugs with intrinsic sympathomimetic activity. Most evidence is available for propranolol, timolol, and metoprolol. In long term trials, the number needed to treat for 2 years to avoid a death is 42, which compares favourably with other treatments for patients with acute or past myocardial infarction. CONCLUSIONS: beta Blockers are effective in long term secondary prevention after myocardial infarction, but they are underused in such cases and lead to avoidable mortality and morbidity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1136/bmj.318.7200.1730

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Untitled work
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Sleight, R. B., Sleight, P., Parish, S., Appleby, P. N., Collins, R., & Baigent, C. (1988) · PubMed · Cited by 2,868
Comparison of Invasive and Conservative Strategies after Treatment with Intravenous Tissue Plasminogen Activator in Acute Myocardial Infarction
The TIMI Study Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198903093201002 · Cited by 1,024
Effect of Beta-Blockade on Mortality among High-Risk and Low-Risk Patients after Myocardial Infarction
Gottlieb, S. S., McCarter, R., & Vogel, R. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808203390801 · Cited by 966
The Effect of Diltiazem on Mortality and Reinfarction after Myocardial Infarction
The Multicenter Diltiazem Postinfarction Trial Research Group (1988) · New England Journal of Medicine · doi:10.1056/nejm198808183190701 · Cited by 828
Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.
(1994) · Europe PMC (PubMed Central) · Cited by 755
The Effect of Warfarin on Mortality and Reinfarction after Myocardial Infarction
Smith, P., Arnesen, H., & Holme, I. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007193230302 · Cited by 637

Show all 34 references

Research works printed but not linked: 3

Viskin S, Barron HV. -Blockers prevent cardiac death following myocar- dial infarction: so why are so many infarct survivors discharge without -blockers? Am J Cardiol 1996;78:821-2.
Spiegelhalter D, Thomas A, Best N, Gilks W. BUGS: Bayesian inference using Gibbs sampling, Version 0.50. Cambridge: Medical Research Council Biostatistics Unit, 1995.
Feely J, de Vane PJ, Maclean D. -Blockers and sympathomimetics. BMJ 1983;286:1043-7.

Sorted by citations

Items 701–800 of 1,000

Safety of beta-blocker discontinuation after acute coronary syndromes with preserved or mildly reduced left ventricular ejection fraction: a target trial emulation from a real-world cohort
Johner, N., Branca, M., Carballo, D., Baggio, S., Nanchen, D., Tessitore, E., Räber, L., Lüscher, T. F., Matter, C. M., Windecker, S., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae346 · Cited by 13
Revisiting medication use in a frail 93-year-old man experiencing possible adverse effects
Farrell, B. J., Monahan, A., & Thompson, W. (2013) · Canadian Medical Association Journal · doi:10.1503/cmaj.130523 · Cited by 13
Effect of Beta Blockers and Renin–Angiotensin System Inhibitors on Survival in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention
Lee, P. H., Park, G., Kim, Y., Yun, S., Chang, M., Roh, J., Yoon, S.-H., Ahn, J., Park, D., Kang, S., et al. (2016) · Medicine · doi:10.1097/md.0000000000002971 · Cited by 13
Achieving the earliest possible reperfusion in patients with acute coronary syndrome: a current overview
Nakashima, T., & Tahara, Y. (2018) · Journal of Intensive Care · doi:10.1186/s40560-018-0285-9 · Cited by 13
Beta-Blocker Use in Older Hospitalized Patients Affected by Heart Failure and Chronic Obstructive Pulmonary Disease: An Italian Survey From the REPOSI Register
Arcoraci, V., Squadrito, F., Rottura, M., Barbieri, M. A., Pallio, G., Irrera, N., Nobili, A., Natoli, G., Argano, C., Squadrito, G., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.876693 · Cited by 13
Prevention of Ventricular Fibrillation During Acute Myocardial Ischemia: Control of Free Fatty Acids
Oliver, M. F. (2001) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840100600301 · Cited by 13
“While existing beta-blockers have been unsuccessful in reducing early cardiac deaths (34), specific blockade of adipose and muscle lipoprotein lipases should be attainable.”
Background
GUIDELINES ON DIABETES, PRE-DIABETES, AND CARDIOVASCULAR DISEASES
Rydén, L., Standl, E., Bartnik, M., den Berghe, G. V., Betteridge, J. D., de Boer, M. J., Cosentino, F., Jönsson, B., Laakso, M., Malmberg, K., et al. (2007) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2007-3-5-88-111 · Cited by 13
Treatment gaps, 1-year readmission and mortality following myocardial infarction by diabetes status, sex and socioeconomic disadvantage
Morton, J. I., Ilomäki, J., Wood, S. J., Bell, J. S., Huynh, Q. L., Magliano, D. J., & Shaw, J. E. (2022) · Journal of Epidemiology & Community Health · doi:10.1136/jech-2021-218042 · Cited by 14
Post–myocardial infarction β-blocker therapy: The bradycardia conundrum. Rationale and design for the Pacemaker & β-blocker therapy post-MI (PACE-MI) trial
Goldberger, J. J., Bonow, R. O., Cuffe, M. S., Dyer, A. R., Greenland, P., Rosenberg, Y., O’Rourke, R. A., Shah, P. K., & Smith, S. C. (2008) · American Heart Journal · doi:10.1016/j.ahj.2007.10.041 · Cited by 13
Chronic kidney disease in patients with cardiac disease: A review of evidence-based treatment
McMurray, J. J. V. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00552.x · Cited by 13
“Beta blockers were the first class of drug shown to improve prognosis after infarction [51].”
Background
Hypertension and its management in countries in Africa and the Middle East, with special reference to the place ofβ-blockade
Arnaout, M. S., Almahmeed, W. A., Ibrahim, M., Ker, J., Khalil, M., Wyk, C. T. V., Mancia, G., & Mousa, E. A. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.576239 · Cited by 13
Clinical pharmacology of antihypertensive drugs
Ram, C. V. S., & Fenves, A. Z. (2002) · Cardiology Clinics · doi:10.1016/s0733-8651(01)00008-x · Cited by 13
Beta-blocker therapy is not associated with symptoms of depression and anxiety in patients receiving an implantable cardioverter-defibrillator
Hoogwegt, M. T., Kupper, N. H. M., Theuns, D. A. M. J., Jordaens, L. J. L. M., & Pedersen, S. S. (2011) · EP Europace · doi:10.1093/europace/eur295 · Cited by 13
Acute Coronary Syndromes
Hamm, C. W., Möllmann, H., Bassand, J., & de Werf, F. V. (2009) · doi:10.1093/med/9780199566990.003.016 · Cited by 13
Evaluación a corto plazo del control de los factores de riesgo y de la prescripción terapéutica en prevención secundaria de enfermedad cardiovascular
de Pablo, C. C., Portillo, A., Palanco, M. Á. M., Luis, C. S., Sanz, P. I., & Fernández, C. S. (2005) · Revista Clínica Española · doi:10.1157/13079070 · Cited by 13
Alpha-crystallin: an ATP-independent complete molecular chaperone toward sorbitol dehydrogenase
Marini, I., Moschini, R., CORSO, A. D., & Mura, U. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-4474-z · Cited by 13
Beta-blockers for heart failure
Cleland, J. G. F., Freemantle, N., Eastaugh, J., Young, P. J., & Harrison, J. (2000) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002131 · Cited by 13
Self-citation
Retracted
Beta-blockers after acute myocardial infarction: an old drug in urgent need of new evidence!
Harari, R., & Bangalore, S. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa436 · Cited by 13
Inadequate heart rate control is associated with worse quality of life in patients with coronary artery disease and chronic obstructive pulmonary disease. The RYTHMOS study.
Andrikopoulos, G. K., Pastromas, S. C., Kartalis, A. N., Toli, K., Mantas, I., Tzeis, S. E., Kyrpizidis, C., Olympios, C. D., Manolis, A. J., Foussas, S. G., et al. (2012) · PubMed · Cited by 12
Heart failure with mid-range ejection fraction and the effect of β-blockers after acute myocardial infarction
Song, P. S., Kim, M., Seong, S.-W., Park, J., Choi, S. W., Hahn, J., Gwon, H., Hur, S., Rha, S., Yoon, C., et al. (2021) · Heart and Vessels · doi:10.1007/s00380-021-01876-1 · Cited by 12
Impact of type of dialyzable beta-blockers on subsequent risk of mortality in patients receiving dialysis: A systematic review and meta-analysis
Yeh, T.-H., Tu, K.-C., Hung, K., Chuang, M., & Chen, J. (2022) · PLoS ONE · doi:10.1371/journal.pone.0279680 · Cited by 13
Promising tools for future drug discovery and development in antiarrhythmic therapy
Mondéjar‐Parreño, G., Sánchez-Pérez, P., Cruz, F. M., & Jalife, J. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.001297 · Cited by 14
Beta-blockeRs tO patieNts with CHronIc Obstructive puLmonary diseasE (BRONCHIOLE) – Study protocol from a randomized controlled trial
the BRONCHIOLE investigators, Sundh, J., Magnuson, A., Montgomery, S., Andell, P., Rindler, G., & Fröbert, O. (2020) · Trials · doi:10.1186/s13063-019-3907-1 · Cited by 11
Association of β-Blocker Therapy at Discharge with Clinical Outcomes after Acute Coronary Syndrome in Patients without Heart Failure
Chen, Y., Tang, X., Gao, R.-L., Yang, Y., Xu, B., & Yuan, J. (2020) · Cardiovascular Therapeutics · doi:10.1155/2020/4351469 · Cited by 12
“These recommendations are mainly drawn from studies conducted in the prereperfusion era [6] or studies of heart failure (HF) [7] patients.”
Background
Ischemia-reperfusion myocardial infarction induces remodeling of left cardiac-projecting stellate ganglia neurons
Barrett, M. S., Bauer, T. C., Li, M., Hegarty, D. M., Mota, C. M. D., Amaefuna, C., Ingram, S., Habecker, B. A., & Aicher, S. A. (2023) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00582.2023 · Cited by 12
ST-Segment Elevation Myocardial Infarction
Enriquez, J. R., & de Lemos, J. A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6705-2_26 · Cited by 13
Influence of non-ventilatory options on postoperative outcome
Chappell, D., & Jacob, M. (2010) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2010.02.004 · Cited by 12
Blockade by Nanomolar Resveratrol of Quantal Catecholamine Release in Chromaffin Cells
Fernández‐Morales, J., Yáñez, M., Orallo, F., Cortés, L., Gonzalez, J., Hernández-Guijo, J. M., de Diego, A. M. G., & de Diego, A. M. G. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.066423 · Cited by 13
“In fact, blockers of -adrenergic receptors are cardioprotective in this clinical setting and in myocardial infarction (Freemantle et al., 1999).”
Background
Discontinuation of secondary prevention medication after myocardial infarction – the role of general practitioners and patients
Bally, K., Buechel, R. R., Buser, P. T., Martina, B., Tschudi, P., & Zeller, A. (2013) · Swiss Medical Weekly · doi:10.4414/smw.2013.13896 · Cited by 12
Contribution of Hepatitis B to Long-Term Outcome Among Patients With Acute Myocardial Infarction
Kuo, P., Lin, K.-C., Tang, P., Cheng, C.-C., Huang, W., Chiang, C., Lin, H.-C., Chuang, T.-J., Wann, S., Mar, G.-Y., et al. (2016) · Medicine · doi:10.1097/md.0000000000002678 · Cited by 12
Contemporary Drug Treatment of Hypertension: Focus on Recent Guidelines
Aronow, W. S., & Frishman, W. H. (2018) · Drugs · doi:10.1007/s40265-018-0887-5 · Cited by 12
The Use of Oral Beta-Blockers and Clinical Outcomes in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: a Long-Term Follow-Up Study
Nicolau, J. C., Furtado, R. H. M., Baracioli, L., Lara, L. M., Dalçóquio, T. F., Scanavini, M. A., Pereira, C., Lima, V., Gonçalves, T. M., Colodetti, R., et al. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6818-6 · Cited by 12
A sensitive liquid chromatography-tandem mass spectrometric method for determination of five β-blockers after labeling with either hydrazonoyl chloride or dansyl chloride reagent
Khedr, A., Khayyat, A. N., El‐Shorbagi, A., & Kammoun, A. K. (2020) · Journal of Chromatography B · doi:10.1016/j.jchromb.2020.122383 · Cited by 12
Recomendaciones preventivas cardiovasculares PAPPS del 2009
Galán, A. M., Cuixart, C. B., Álvarez, F. V., Lobos-Bejarano, J. M., Laguna, J. T., Orozco‐Beltrán, D., Pérez, J. N., Ortega, R., Gil-Guillén, V. F., & Canals, J. (2009) · Cited by 12
Use of Perioperative Cardiac Medical Therapy Among Patients Undergoing Coronary Artery Bypass Graft Surgery
Filion, K. B., Pilote, L., Rahme, E., & Eisenberg, M. J. (2008) · Journal of Cardiac Surgery · doi:10.1111/j.1540-8191.2008.00596.x · Cited by 12
A Modern Perspective on β‐Blocker Use in Hypertension: Clinical Trials and Their Influence on Clinical Practice
Black, H. R., & Sica, D. A. (2007) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2007.06652.x · Cited by 12
eNOS Overexpressing Bone Marrow Cells are Safe and Effective in a Porcine Model of Myocardial Regeneration Following Acute Myocardial Infarction
Ward, M. R., Connelly, K. A., Vijayaraghavan, R., Vaags, A. K., Graham, J. J., Foltz, W. D., Hough, M. R., Stewart, D. J., & DICK, A. J. (2013) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12037 · Cited by 12
Skin prick testing in patients using beta-blockers: a retrospective analysis
Fung, I. N., & Kim, H. L. (2010) · Allergy Asthma and Clinical Immunology · doi:10.1186/1710-1492-6-2 · Cited by 12
Secondary Prevention Beyond Hospital Discharge for Acute Coronary Syndrome: Evidence-Based Recommendations
FITCHETT, D. H., Goodman, S. G., Leiter, L. A., Lin, P., Welsh, R. C., Stone, J. A., Grégoire, J. C., McFarlane, P. A., & Langer, A. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.03.002 · Cited by 12
Comparison of short‐term clinical outcomes of proximal versus nonproximal lesion location in patients treated with primary percutaneous coronary intervention for ST‐elevation myocardial infarction: The PROXIMITI study
Noaman, S. Q., Goh, C. Y., Vogrin, S., Brennan, A., Andrianopoulos, N., Dinh, D. T., Lefkovits, J., Reid, C. M., Walton, A., Al‐Mukhtar, O., et al. (2018) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.27665 · Cited by 12
Use of β-blockers and effects on heart rate and blood pressure post-acute coronary syndromes: Are we on target?
Herman, M., Donovan, J. L., Tran, M. T., McKenna, B., Gore, J. M., Goldberg, R. J., & Tighe, D. A. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.06.023 · Cited by 12
Medical therapy or coronary artery bypass graft surgery for chronic stable angina: an update using decision analysis
Kwok, Y. S., Kim, C., & Heidenreich, P. A. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00768-9 · Cited by 12
Nurse-led titration of angiotensin converting enzyme inhibitors, beta-adrenergic blocking agents and angiotensin receptor blockers for patients with left ventricular systolic dysfunction
Driscoll, A. L., Currey, J., Tonkin, A., & Krum, H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009889 · Cited by 12
Beta-blocker therapy and primary angioplasty
Faxon, D. P. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.03.001 · Cited by 12
Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction
Cleland, J. G. F., McMurray, J. J. V., & Freemantle, N. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2406095 · Cited by 13
Self-citation
2025 Clinical practice guidelines for Ventricular arrhythmias of the heart and Sudden cardiac death
Mikhailov, E. N., Gizatulina, T. P., Lebedev, D. S., Golukhova, E. Z., Kharlap, M. S., Лебедева, В. К., Bagnenko, S. F., Artyukhina, Е. А., Babokin, V. E., Batalov, R. E., et al. (2026) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6670 · Cited by 14
Drug Class Review on Beta Adrenergic Blockers: Final Report
Helfand, M., Peterson, K., & Dana, T. (2007) · Europe PMC (PubMed Central) · Cited by 11
Principles of Systematic Reviewing
Higgins, J. P. T., Smith, G. D., Altman, D. G., & Egger, M. (2022) · Wiley eBooks · doi:10.1002/9781119099369.ch2 · Cited by 11
Routine beta‐blocker therapy after acute coronary syndromes: The end of an era?
Johner, N., Gencer, B., & Roffi, M. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14309 · Cited by 11
Beta-Blockers in Patients with Myocardial Infarction and Preserved Left Ventricular Ejection: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Sabina, M., Shah, S., Grimm, M., Daher, J. C., Campillo, P., Boozo, M. B., Al‐Abdouh, A., Abusnina, W. A., ́ascenzo, F. D., & Bizanti, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm14010150 · Cited by 11
Increasing evidence-based treatments to reduce coronary heart disease mortality in Sweden: quantifying the potential gains
Bjorck, L. M., Capewell, S., Bennett, K., Lappas, G., & Rosengren, A. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02339.x · Cited by 11
56: Beta-Blocker Use and the Changing Epidemiology of Out-of-Hospital Cardiac Arrest Rhythms
Youngquist, S. T., Kaji, A. H., & Niemann, J. T. (2008) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2008.01.023 · Cited by 11
Modulación del sistema betaadrenérgico durante el infarto agudo de miocardio: justificación para un nuevo ensayo clínico
Ibáñez, B., Fuster, V., Macaya, C., Jiménez‐Borreguero, L. J., Íñiguez, A., Fernández‐Ortíz, A., Sanz, G., & Sánchez-Brunete, V. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.02.028 · Cited by 11
Chronic β 1 -adrenoceptor blockade impairs ischaemic tolerance and preconditioning in murine myocardium
Hoe, L. E. S., Schilling, J. M., Busija, A. R., Haushalter, K. J., Ozberk, V., Keshwani, M. M., Roth, D. M., Toit, E. D., Headrick, J. P., Patel, H. H., et al. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.06.054 · Cited by 11
Secondary preventive medication use in a prevalent population‐based cohort of acute coronary syndrome survivors
Gunnell, A. S., Hung, J., Knuiman, M. W., Nedkoff, L., Gillies, M. B., Geelhoed, E. A., HOBBS, M. S. T., Katzenellenbogen, J. M., Rankin, J. M., Ortiz, M. S., et al. (2016) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12212 · Cited by 11
Effect of evidence‐based cardiac drug therapy on mortality in patients with acute coronary syndrome: Findings from the Gulf COAST registry
Al-Zakwani, I. S., Zubaid, M., Alsheikh-Ali, A. A. A., Almahmeed, W. A., & Rashed, W. A. (2018) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12463 · Cited by 11
β-blockers after myocardial infarction and 1-year clinical outcome – a retrospective study
Hagsund, T., Olsson, S.-E., Smith, J. G., Härdig, B. M., & Wagner, H. (2020) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01441-0 · Cited by 11
One-step synthesis of well-defined molecularly imprinted nanospheres for the class-selective recognition and separation of β-blockers in human serum
Hou, H., Jin, Y., Sheng, L., Huang, Y., & Zhao, R. (2022) · Journal of Chromatography A · doi:10.1016/j.chroma.2022.463204 · Cited by 11
Ventricular Tachycardia and Sudden Cardiac Death
Eckardt, L., BREITHARDT, G. E., & Hohnloser, S. H. (2009) · doi:10.1093/med/9780199566990.003.030 · Cited by 11
Mortality reduction with use of oral beta-blockers in patients with acute coronary syndrome
Soeiro, A. D. M., Silva, P. G. M. D. B. E., Roque, E. A. D. C., Bossa, A. S., Zullino, C. N., Simões, S. A., Okada, M. Y., Leal, T. D. C. A. T., Soeiro, M. C. F. D. A., Junior, C. V. S., et al. (2016) · Clinics · doi:10.6061/clinics/2016(11)03 · Cited by 11
β‐Blocker Therapy Prior to Admission for Acute Coronary Syndrome in Patients Without Heart Failure or Left Ventricular Dysfunction Improves In‐Hospital and 12‐Month Outcome: Results From the GULF‐RACE 2 (Gulf Registry of Acute Coronary Events‐2)
Khalil, C. A., AlHabib, K. F., Singh, R., Asaad, N., AlFaleh, H., Alsheikh-Ali, A. A. A., Sulaiman, K., Alshamiri, M. Q., Alshaer, F., Almahmeed, W. A., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.007631 · Cited by 11
Effect of β-blocker therapy in diabetic patients with stable coronary heart disease: a meta-analysis.
Malik, A. H., Shetty, S. S., Kar, K., & Accaoui, R. N. E. (2019) · PubMed Central · doi:10.11909/j.issn.1671-5411.2019.03.008 · Cited by 11
β2‐Adrenergic Receptor Gene Affects the Heart Rate Response of β‐Blockers: Evidence From 3 Clinical Studies
Shahin, M. H., Rouby, N. M. E., Conrado, D. J., González, D., Gong, Y., Lobmeyer, M. T., Beitelshees, A. L., Boerwinkle, E., Gums, J. G., Chapman, A. B., et al. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1443 · Cited by 11
Differential Effect of β-Blockers According to Heart Rate in Acute Myocardial Infarction Without Heart Failure or Left Ventricular Systolic Dysfunction: A Cohort Study
Park, J. J., Kim, S., Kang, S., Yoon, C., Suh, J., Cho, Y., Youn, T., Chae, I., & Choi, D. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.05.033 · Cited by 11
Class effect of beta-blockers in survivors of ST-elevation myocardial infarction: A nationwide cohort study using an insurance claims database
Lin, T., Chan, K. A., Chen, H., Lai, C., & Lai, M. (2015) · Scientific Reports · doi:10.1038/srep13692 · Cited by 11
Secondary Prevention in Concurrent Coronary Artery, Cerebrovascular, and Chronic Kidney Disease: Focus on Pharmacological Therapy
Notaro, L. A., Usman, M. H., Burke, J. F., Siddiqui, A., Superdock, K. R., & Ezekowitz, M. D. (2009) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2009.00087.x · Cited by 12
Are β-blockers truly helpful in patients with CAD?
Danchin, N., & Laurent, S. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.159 · Cited by 11
Is the beta3-adrenergic receptor a new target for treatment of post-infarct ventricular tachyarrhythmias and prevention of sudden cardiac death?
Fedorov, V. V., & Lozinsky, I. T. (2007) · Heart Rhythm · doi:10.1016/j.hrthm.2007.10.037 · Cited by 11
Hymenopterengiftanaphylaxie und Herz-Kreislauf-Erkrankungen
Müller, U. R. (2008) · Der Hautarzt · doi:10.1007/s00105-008-1469-3 · Cited by 11
Population impact of stricter adherence to recommendations for pharmacological and lifestyle interventions over one year in patients with coronary heart disease
Gemmell, I., Heller, R. F., McElduff, P., Payne, K., Butler, G., Edwards, R., Roland, M., & Durrington, P. N. (2005) · Journal of Epidemiology & Community Health · doi:10.1136/jech.2005.035717 · Cited by 11
Synthesis, β-adrenoceptor pharmacology and toxicology of S-(−)-1-(4-(2-ethoxyethoxy)phenoxy)-2-hydroxy-3-(2-(3,4-dimethoxyphenyl)ethylamino)propane hydrochloride, a short acting β1-specific antagonist
Jackman, G. P., Iakovidis, D., Nero, T. L., Anavekar, N. S., Rezmann, L. A., Louis, S. N. S., Mori, M., Drummer, O. H., & Louis, W. J. (2002) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(02)01399-5 · Cited by 11
Incidence and prognosis of cardiopulmonary arrest due to acute myocardial infarction in 85 consecutive patients
Takahashi, M., Kondo, Y., Senoo, K., Fujimoto, Y., & Kobayashi, Y. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2018.04.001 · Cited by 11
The pharmaco-economics of peri-operative beta-blocker and statin therapy in South Africa.
Biccard, B. M., Sear, J. W., & Foëx, P. (2006) · PubMed · Cited by 11
Clinical trial data on the cardioprotective effects of beta-blockade
Kendall, M. J. (2000) · Basic Research in Cardiology · doi:10.1007/s003950070005 · Cited by 11
Significance of hypotensive response during dobutamine stress echocardiography
Dunkelgrün, M., Hoeks, S. E., Elhendy, A., van Domburg, R. T., Bax, J. J., Noordzij, P. G., Feringa, H. H. H., Vidaković, R., Karagiannis, S. E., Schouten, O., et al. (2007) · International Journal of Cardiology · doi:10.1016/j.ijcard.2007.02.058 · Cited by 11
A New Framework for Describing and Quantifying the Gap Between Proof and Practice
Sim, I., & Cummings, S. R. (2003) · Medical Care · doi:10.1097/00005650-200308000-00002 · Cited by 11
The Effectiveness of β-Blockers After Myocardial Infarction in Patients With Type 2 Diabetes
McDonald, C. G., Majumdar, S. R., Mahon, J. L., & Johnson, J. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2113 · Cited by 11
Does Obstructive Sleep Apnea Treatment Reduce Cardiovascular Risk?
Gottlieb, D. J. (2017) · JAMA · doi:10.1001/jama.2017.7966 · Cited by 11
Beta blockers are associated with lower all-cause mortality among HFpEF patients
Ibrahim, J., Fabrizio, C. A., Sezer, A., Thoma, F. W., Boyle, B., Mulukutla, S. R., Huston, J., Simon, M. A. M., & Hickey, G. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-024-02451-0 · Cited by 11
Pharmacological and Device-Based Intervention for Preventing Heart Failure After Acute Myocardial Infarction ― A Clinical Review ―
Saito, Y., Kobayashi, Y., Tsujita, K., Kuwahara, K., Ikari, Y., Tsutsui, H., Kinugawa, K., & Kozuma, K. (2024) · Circulation Journal · doi:10.1253/circj.cj-24-0633 · Cited by 12
Should β-blockers still be routine after myocardial infarction?
Thompson, P. L. (2013) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328361e97a · Cited by 10
Prognostic Impact of Acute Beta-Blocker Therapy on Top of Aspirin and Angiotensin-Converting Enzyme Inhibitor Therapy in Consecutive Patients With ST-Elevation Acute Myocardial Infarction
Wienbergen, H., Zeymer, U., Gitt, A. K., Juenger, C., Schiele, R., Heer, T., Towae, F., & Senges, J. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.12.036 · Cited by 10
Long-Term Quality of Prescription for ST-Segment Elevation Myocardial Infarction (STEMI) Patients: A Real World 1-Year Follow-Up Study
Bruggmann, C., Iglesias, J. F., Gex‐Fabry, M., Fesselet, R., Vogt, P., Sadeghipour, F., & Voirol, P. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00361-5 · Cited by 10
Beta-blockers in patients with chronic obstructive disease and coexistent cardiac illnesses
Puente‐Maestu, L., Alvarez-Sala, L. A., & de Miguel‐Díez, J. (2015) · COPD Research and Practice · doi:10.1186/s40749-015-0013-y · Cited by 10
Effect of early bisoprolol administration on ventricular arrhythmia and cardiac death in patients with non-ST elevation myocardial infarction
Maclean, E., Zheng, S. L., Nabeebaccus, A., O’Gallagher, K., Stewart, A. J., & Webb, I. G. (2015) · Heart Asia · doi:10.1136/heartasia-2015-010675 · Cited by 10
Extreme Sodium Reductions for the Entire Population: Zealotry or Evidence Based?
Mente, A., O'Donnell, M. J., & Yusuf, S. (2013) · American Journal of Hypertension · doi:10.1093/ajh/hpt148 · Cited by 10
Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Adaptación española del CEIPC 2008
Lobos, J. M., Royo‐Bordonada, M. Á., Brotons, C., Álvarez-Sala, L., Armario, P., Maiques, A., Mauricio, D., Sans, S., Villar, F., Lizcano‐Álvarez, A., et al. (2009) · Hipertensión y Riesgo Vascular · doi:10.1016/s1889-1837(09)72176-2 · Cited by 10
Rationale for administering beta-blocker therapy to patients undergoing coronary artery bypass surgery: a systematic review
Thaper, A., & Kulik, A. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1504019 · Cited by 11
“reported a 23% reduction in the odds of death when beta-blockers were used for long-term secondary prevention after MI [19].”
Background
Selection of β‐Blocker in Patients With Cirrhosis and Acute Myocardial Infarction: A 13‐Year Nationwide Population‐Based Study in Asia
Wu, V. C., Chen, S., Ting, P., Chang, C., Michael Shengtao, W. U., Lin, M., Hsieh, M., Wang, C., Chang, S., Hung, K., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008982 · Cited by 10
What is the role of beta-blockers in a contemporary treatment cohort of patients with acute coronary syndrome? A propensity-score matching analysis
Timóteo, A. T., Rosa, S. A., Cruz, M., Moreira, R. I., Carvalho, R. S., Ferreira, M. L., & Ferreira, R. C. (2018) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2017.11.016 · Cited by 10
Comparison of Outcomes with or without Beta-Blocker Therapy After Acute Myocardial Infarction in Patients Without Heart Failure or Left Ventricular Systolic Dysfunction (from the Acute Coronary Syndromes Israeli Survey [ACSIS])
Nasasra, A. E., Beigel, R., Klempfner, R., Alnsasra, H., Matetzky, S., Iakobishvili, Z., Rubinshtein, R., Halabi, M., Blatt, A., & Zahger, D. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.12.044 · Cited by 10
Influence of left ventricular systolic function on the long-term benefit of beta-blockers after ST-segment elevation myocardial infarction
Velásquez‐Rodríguez, J., Bruña, V., Vicent, L., Díez‐Delhoyo, F., Valero‐Masa, M. J., Sousa-Casasnovas, I., Juárez, M., Devesa, C., Fernández‐Avilés, F., & Martínez‐Sellés, M. (2021) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2020.07.017 · Cited by 11
Prognostic impacts of β-blockers in acute coronary syndrome patients without heart failure treated by percutaneous coronary intervention
Chen, R., Liu, C., Zhou, P., Li, J., Zhou, J., Wang, Y., Zhao, X., Chen, Y., Li, S., Zhao, H., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105614 · Cited by 10
Sympathetic hyperactivity in patients with hypertension: pathogenesis and treatment. Part I
Safaryan, A. S., & Sargsyan, V. D. (2020) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2020-2693 · Cited by 12
Part 10: Pediatric Advanced Life Support
guidelines, I. T. P. O. T., guidelines, W. R. T. C. T. T. A. C. I. T. U. S. A. U. I. A. V. V. B. T. A. I., confusion, E. W. M. T. U. T. C. T. T. A., & terms:, T. R. S. N. T. U. O. T. F. (2000) · Circulation · doi:10.1161/circ.102.suppl_1.i-291 · Cited by 10
A novel vaccine targeting β1-adrenergic receptor
Fan, K., Kuang, W., Hu, X., Li, C., Ma, W., Shi, D., Li, X., Wu, Z., Zhou, Y., Liao, Y., et al. (2023) · Hypertension Research · doi:10.1038/s41440-023-01265-3 · Cited by 10
Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Adaptación española del CEIPC 2008
Bejarano, J. M. L., Royo‐Bordonada, M. Á., Brotons, C., Álvarez-Sala, L., Armario, P., Maiques, A., Mauricio, D., Sans, S., Villar, F., Lizcano‐Álvarez, A., et al. (2009) · Atención Primaria · doi:10.1016/j.aprim.2008.10.024 · Cited by 11
Prevención secundaria post infarto agudo de miocardio en hospitales públicos: implementación y resultados de las garantías GES
Carolina Nazzal, N., Lanas, F. T., Garmendia, M. L., Bugueño, C., Mercadal, E., Eduardo Garcés, S., Yovaniniz, P., & Sanhueza, P. (2013) · Revista médica de Chile · doi:10.4067/s0034-98872013000800003 · Cited by 10
β-Blocker Compliance, Mortality, and Reinfarction: Validation of Clinical Trial Association Using Insurer Claims Data
Kleiner, S. A., Vogt, W. B., Gladowski, P., DEVRIES, A. R., Levin, G., Antonucci, C., & Fong, J. (2009) · American Journal of Medical Quality · doi:10.1177/1062860609345003 · Cited by 10
Unstable angina: the first 48 hours and later in-hospital management
Newby, D. E., & Fox, K. A. A. (2001) · British Medical Bulletin · doi:10.1093/bmb/59.1.69 · Cited by 10

Authors: Freemantle, N., Cleland, J., Young, P., Mason, J., & Harrison, J.
Affiliations: University of York (GB)
University of Hull (GB)
Corresponding author: Freemantle, N.
ORCID: Freemantle, N.
Cleland, J.
Mason, J.
Venue: BMJ
Publisher: BMJ
Published: 1999-06-26
Volume: 318
Issue: 7200
Pages: 1730-1737
ISSN: 0007-1447 (ISSN-L)
0959-8138
1468-5833
DOI: 10.1136/bmj.318.7200.1730
PMC: PMC31101
OpenAlex: W2070568974
Cited by: 1,509
References: 34
Citations by year: 2026: 27 · 2025: 43 · 2024: 38 · 2023: 30 · 2022: 42 · 2021: 36 · 2020: 49 · 2019: 47 · 2018: 53 · 2017: 57 · 2016: 58 · 2015: 48 · 2014: 67 · 2013: 74 · 2012: 83
FWCI: 7.55
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: BMJ (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
HighWire Press Open Archive (submittedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Ischemia and Reperfusion
Keywords: beta-blockers, myocardial infarction, secondary prevention, all-cause mortality, reinfarction, cardioselectivity, intrinsic sympathomimetic activity, propranolol, timolol, metoprolol, number needed to treat, predictors of treatment response
MeSH terms: Adrenergic beta-Antagonists, Humans, Myocardial Infarction, Regression Analysis, Randomized Controlled Trials as Topic, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

beta Blockade after myocardial infarction: systematic review and meta regression analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks